Propanc Biopharma, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $2.5M
- Price
- $1.08
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.82%
- Volume
- 25.2K
About
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.
Quick stats
Shares outstanding2.3M
Computed float1.6M
Float / shares71.5%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001517681
Websitehttps://www.propanc.com
AI Summary
AI-generated1/22
standardbullishclinical trial
Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP
Propanc Biopharma has commenced finalization of the clinical trial protocol and a feasibility assessment for its First-In-Human Phase 1b study of PRP in up to 40 advanced cancer patients with solid tumors.
The study, led by CRO Avance Clinical, will be a multicenter, open-label dose escalation and expansion trial designed to evaluate safety, tolerability, and preliminary activity.
The company plans to submit a Clinical Trial Application in Q4 2026, aiming to advance its lead candidate targeting cancer recurrence and metastasis.